Ernesto Bosch, M.D.
Vol 97, Issue 6 , Pages 1299-1300
Gonadotropin-releasing hormone (GnRH) antagonists were introduced into clinical practice more than a decade ago. However, although they offer a number of advantages compared with GnRH agonists, their introduction in daily practice has been slower than initially could be expected. A major drawback for their consolidation has been the limitation for programming cycles, as when the GnRH antagonist protocol gonadotropin administration is started on day 2 or 3 of menses, which is clearly an unpredictable event.
Read the full text at: http://www.fertstert.org/article/S0015-0282(12)00479-7/fulltext